McDonald's Corporation vs F. Hoffmann-La Roche AG: Strategic Comparison

This in-depth comparison examines McDonald's Corporation and F. Hoffmann-La Roche AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching McDonald's Corporation on its own, evaluating F. Hoffmann-La Roche AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between McDonald's Corporation and F. Hoffmann-La Roche AG is widest.

On the headline numbers, McDonald's Corporation reports annual revenue of $26.9B against $77.2B for F. Hoffmann-La Roche AG, while their respective market capitalizations stand at $188.3B and $327.5B. McDonald's Corporation is headquartered in United States and F. Hoffmann-La Roche AG operates from Switzerland, and those different home markets shape how each company competes.

McDonald's Corporation: McDonald's is the world's defining quick-service restaurant system. In FY2025, it reported $26.885 billion of consolidated revenue, $8.563 billion of net income, and 45,356 restaurants. Corporate revenue is much smaller than systemwide sales because franchisees record most restaurant sales, while McDonald's books rent, royalties, fees, and company-operated revenue.

F. Hoffmann-La Roche AG: Roche is not just a drug company with a diagnostics side business. Its strategic identity is an integrated healthcare model: test the patient, identify the biology, treat with a targeted therapy, and use outcome data to improve the next development cycle.

McDonald's Corporation and F. Hoffmann-La Roche AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between McDonald's Corporation and F. Hoffmann-La Roche AG.

McDonald's Corporation business model: McDonald's makes money from franchise royalties, rent, fees, and company-operated restaurant sales. The most powerful part of the model is that franchisees provide most restaurant-level labor and capital, while McDonald's controls brand standards, menu systems, supplier relationships, site economics, digital platforms, and real estate in many markets.

F. Hoffmann-La Roche AG business model: Roche makes money from branded prescription medicines, biologics, oncology and specialty drugs, diagnostic instruments, diagnostic reagents, sequencing and molecular testing, diabetes care products, and clinical data assets. Pharmaceuticals drive the largest share of sales, while Diagnostics adds recurring reagent revenue and supports personalized healthcare.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of McDonald's Corporation stack up against those of F. Hoffmann-La Roche AG.

McDonald's Corporation competitive advantage: McDonald's advantage comes from global brand recognition, restaurant density, drive-thru scale, franchisee capital, real estate control, supplier systems, operating standards, digital loyalty data, and the ability to run value promotions across a huge system.

F. Hoffmann-La Roche AG competitive advantage: Roche's advantage is the combination of drug development, diagnostics, Genentech biotechnology depth, companion diagnostic capability, and oncology data assets from Foundation Medicine and Flatiron Health. Competitors can match pieces of this model, but few can connect medicines, tests, and real-world data at similar scale.

Future prospects matter as much as current results. The growth strategies below explain how McDonald's Corporation and F. Hoffmann-La Roche AG each plan to expand from here.

McDonald's Corporation growth strategy: McDonald's growth strategy centers on restaurant expansion, core menu strength, value platforms, chicken growth, digital ordering, MyMcDonald's Rewards, delivery partnerships, drive-thru throughput, restaurant modernization, and franchisee execution under the Accelerating the Arches framework.

F. Hoffmann-La Roche AG growth strategy: Roche is investing in late-stage medicines, diagnostics platforms, sequencing, companion diagnostics, real-world evidence, and selective acquisitions that strengthen oncology, immunology, neuroscience, and cardiovascular-metabolic disease areas.

A closer look at the financial trajectory of McDonald's Corporation and F. Hoffmann-La Roche AG rounds out the comparison.

McDonald's Corporation: McDonald's revenue grew from $25.494 billion in FY2023 to $25.920 billion in FY2024 and $26.885 billion in FY2025. FY2025 net income was $8.563 billion, reflecting the power of a franchise-heavy model where corporate income is less exposed to restaurant-level labor and food costs than a mostly company-operated chain would be.

F. Hoffmann-La Roche AG: Roche reported CHF 61.5 billion in 2025 group sales. Pharmaceuticals sales were CHF 47.7 billion and Diagnostics sales were CHF 13.8 billion. Core operating profit was CHF 21.8 billion, and R&D core investments were CHF 12.2 billion. For USD comparability, this profile converts CHF 61.5 billion at 1 CHF = 1.25506 USD.